English
Home > Products > CAS NO 112809-51-5

China CAS NO 112809-51-5 Factory

Often customer-oriented, and it's our ultimate target to become not only probably the most reputable, trustable and honest provider, but also the partner for our customers for CAS NO 112809-51-5,112809-51-5,Letrozole API,Letrozole, If possible, make sure you send your necessities with a detailed list including the style/item and quantity you require. We'll then mail our greatest selling prices to you.
CAS NO 112809-51-5, Now, we are trying to enter new markets where we do not have a presence and developing the markets we have now the already penetrated. On account of superior quality and competitive price , we'll be the market leader, please don??￥t hesitate to contact us by phone or email, if you are interested in any of our goods.

Related Products

Hot Products

  • Econazole nitrate

    Econazole nitrate

    Product Name:Econazole nitrate
    Molecular Formula:C18H16Cl3N3O4
    Molecular Weight;444.7
    CAS Registry Number;24169-02-6
  • 7,10-Dimethoxy-10-DAB III

    7,10-Dimethoxy-10-DAB III

    Product Name:7,10-Dimethoxy-10-DAB III
    Molecular Formula:C31H40O10
    Molecular Weight:572.64
    CAS Registry Number:183133-94-0
  • Polyoxymethylene

    Polyoxymethylene

    Product Name:Polyoxymethylene
    Molecular Formula:C3H6O3X2
    Molecular Weight:90.08
    CAS Registry Number:9002-81-7
  • Ibrutinib

    Ibrutinib

    Product Name:Ibrutinib
    Molecular Formula:C25H24N6O2
    Molecular Weight;440.5
    CAS Registry Number;936563-96-1
  • (-)-Diisopinocampheyl chloroborane

    (-)-Diisopinocampheyl chloroborane

    Product Name:(-)-Diisopinocampheyl chloroborane
    Molecular Formula:C20H34BCl
    Molecular Weight:320.75
    CAS Registry Number:85116-37-6
  • Olutasidenib

    Olutasidenib

    Product Name:Olutasidenib
    Molecular Formula:C18H15ClN4O2
    Molecular Weight;354.79
    CAS Registry Number;1887014-12-1
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept